An interventional study of Ethanol gel and Prednisolone acetate in Lumbar Discogenic Pain (Disorder), sponsored by Gelscom SAS. Recruiting at 5 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-29.
Sponsored by Gelscom SAS · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 482 studies in Pain with a site in France — 75 open to participants now, 79 under way, 8 of them phase 3. Pain · France.
Among the 482 studies in Pain with a site in France, this one is the 43rd largest by planned enrollment of the 369 interventional ones that give a count, is one of 22 that started in 2018, is one of 225 with no phase, reaches primary completion later than 4 of the 78 other live ones, and was the 255th registered.
10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.
Browse Pain studies →75 of the 482 studies in Pain with a site in France are open now. Recruiting first, the newest first:
University Hospital, Angers · Sites in France
Ages 18–120
Farraj Miguel · Sites in France, Belgium
Ages 18+
University Hospital, Toulouse · Sites in France
Ages 18+
University Hospital, Limoges · Sites in France
Ages 18–50 · Women only
Teleflex · Sites in France, United States, Latvia and 1 more country
Ages 18–80
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
482 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 33 · Phase 3 83 · Phase 4 29
First in 2000; this study’s year is marked. 22 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 230 is above the median of 66 across 8,505 interventional studies indexed under Pain.
Median enrollment 80 across the 369 interventional studies, 100 across the 112 observational. Of the 348 that completed or were terminated, 31 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
68 of 482 have an industry lead sponsor. The 10 most frequent:
Gelscom SAS is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Gelscom SAS has 1 study filed under Pain — fewer than ten, so there is no comparison to draw.
24 of the studies in Pain with a site in France that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06381063Phase 3Centre Hospitalier Universitaire, AmiensNon-steroidal Anti-inflammatory in Cardiac Surgery | 2027-03 |
| NCT06917651Phase 3University Hospital, Clermont-FerrandManagement of Moderate to Severe Monotraumatic Pain With Sublingual Sufentanil in an Emergency Situation. | 2027-04-22 |
| NCT07668050University Hospital, Clermont-FerrandA Study of the Impact of a Virtual Reality Medical Device (HypnoVR® Headset) on Anxiety and Pain in Interventional Radiology. | 2026-12 |
| NCT06779812Clinique BizetImpact of Auriculotherapy on Postoperative Pain in Patients Undergoing Surgery for SCC | 2026-12 |
| NCT07627490University Hospital, ToulouseThe Potential of Transcutaneous Electrical Nerve Stimulation to Improve Pain Experienced During Posterior Branch Blocks in Patients With Lumbar Posterior Joint Syndrome | 2026-12-01 |
Add all 24 to your calendar (.ics) → With an account.
Among the 482 studies in Pain with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
DISCOGEL® is on the market since 2007. About 20,000 kits were sold to date (October 2017). The device re-obtained its CE mark in 2017.
A clinical evaluation was performed by bibliographic route in 2016. Clinical data on more than 600 patients treated by DISCOGEL® were analyzed. These data should be confirmed by monitoring on the long term, with a large cohort of patients, over a two-year follow-up period.
As part of the post-CE surveillance, the manufacturer GELSCOM is responsible of this "Post-Market Clinical Follow-up" (PMCF) study in accordance with Directive 93/42/EEC and MEDDEV guide 2.12/2, to assess the efficacy and the long-term safety of DISCOGEL®.
The study is comparative. The results will evaluate the performance and safety of the CE-marked medical device used in "real life", in comparison with a steroid infiltration, used according to its indication and to the current standards. It will include economic data. Patients and evaluators will be blinded. Both DISCOGEL® and HYDROCORTANCYL 2,5 POUR CENT are authorized products used according to their intended use.
This is an interventional, prospective, national, multi-center, comparative, randomized, single-blind (patient and evaluator) post-market clinical study. The primary objective is to compare the short-term efficacy profile of DISCOGEL® versus intradiscal steroid.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CE-marked medical device used according to its instructions for use: GELSCOM® Single injection in the selected disc(s) of 0.6 to 2.2 ml
Device: Ethanol gel
Authorized drug used according to its summary product characteristics: HYDROCORTANCYL 2,5 POUR CENT Single injection in the selected disc(s) of 0.2 to 2.0 ml
Drug: Prednisolone acetate
Intradiscal injection of ethanol gel
Also known as: DISCOGEL®
Intradiscal infiltration of steroids
Also known as: HYDROCORTANCYL 2,5 POUR CENT
Short-term efficacy profile
Compare the short-term efficacy profile of DISCOGEL® versus intradiscal steroid: percentage of patients with a pain relief defined by a Low Back Pain (LBP) intensity\<4 cm on a Local Verbal Rating Scale (0 = no pain to 10 = maximum imaginable pain)
Time frame: Month 3
Long-term efficacy profile
Compare the long-term efficacy profile of DISCOGEL® versus intradiscal steroid: Local Verbal Rating Scale: on back, bottom, thigh, leg, foot
Time frame: Month 12
Long-term efficacy profile
Compare the long-term efficacy profile of DISCOGEL® versus intradiscal steroid: Local Verbal Rating Scale: on back, bottom, thigh, leg, foot
Time frame: Month 24
Short-term safety profile
Analyze the short- and long-term safety profile of DISCOGEL®: rates of complications and adverse reactions
Time frame: Month 3
Long-term safety profile
Analyze the short- and long-term safety profile of DISCOGEL®: rates of complications and adverse reactions
Time frame: Month 12
Long-term safety profile
Analyze the short- and long-term safety profile of DISCOGEL®: rates of complications and adverse reactions
Time frame: Month 24
Questionnaire OSWESTRY
Describe the rate of subjects improved 24 months after treatment: OSWESTRY scale
Time frame: Month 24
Questionnaire MacNab
Subjective improvement 24 months after treatment: MacNab scale
Time frame: Month 24
Radiography
Describe radiologic evolution of the lesions: radiography of the herniated disc
Time frame: Month 3
Radiography
Describe radiologic evolution of the lesions: radiography of the herniated disc
Time frame: Month 12
Radiography
Describe radiologic evolution of the lesions: radiography of the herniated disc
Time frame: Month 24
Magnetic Resonance Imaging
Describe radiologic evolution of the lesions: MRI of the herniated disc
Time frame: Month 3
Procedures costs
Compare the cost linked to the DISCOGEL® procedure and the cost linked to a steroid infiltration or surgery
Time frame: Day 0
Procedures durations
Compare the duration of the treatment procedures between a DISCOGEL® injection and a steroid infiltration or surgery
Time frame: Day 0
Not enrolling at this site.
Not enrolling at this site.
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2018 to primary completion in Feb 2024, 69 months.
Of 99 industry-sponsored interventional studies with no phase under Pain, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's 69 months is above that.
Counting every sponsor, half of 3,839 studies reached it within 10 months; a quarter within 4 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Gelscom SAS